Single Fraction Intraoperative Radiotherapy

St. Joseph Hospital of Orange250 enrolled

Overview

This clinical trial is being conducted to find out the effects (good and bad) of giving the full radiation treatment for breast cancer as a single dose of radiation during surgery for breast cancer. This single fraction intraoperative radiotherapy with electrons will study the toxicity, local control and cosmetic outcome.

For patients with certain types of breast cancer, one standard treatment is breast conserving surgery or lumpectomy (surgery to remove abnormal tissue or cancer from the breast and a small amount of normal tissue around it) followed by breast radiation. The radiation treatment in this situation usually lasts 3 to 5 1/2 weeks followed by 5-8 daily localized irradiation (or boost) treatments at the site where the lump was removed. During this study, the single dose of electron irradiation given at the surgical site during the operation will replace the radiation given after surgery.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

250

Conditions

Invasive Ductal and Invasive Lobular Breast Carcinoma Stage 0 Breast Carcinoma Stage I Breast Carcinoma Stage II Breast Carcinoma

Interventions

Intraoperative RadiotherapyPROCEDURE

Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure. IORT is performed on mobile or fixed linacs with variable electron energies in the range of 6-12 MeV prescribed to a dose of 21 Gy, with the prescription dose covering at least 90% of the Planning Target Volume (PTV). PTV is defined as a 3D volume of 1-2 cm beyond the former macroscopic tumor edge (excluding skin, limit to anterior rib surface: 5 Gy). The choice of electron energy as well as the cone applicator size has to account for minimum PTV requirements. Tissue depth measurement will be documented by intraoperative sonography.

Eligibility

Sex: FEMALEMin age: 41 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histological proven invasive breast carcinoma ductal, lobular and/or Ductal Carcinoma in situ * Age \> 40 years * Karnofsky performance status \> 70% * Tumor. Single discrete tumor or focal microcalcifications that can be imaged on a specimen radiograph or multifocal disease within the same quadrant with a maximum dimension of equal to or less than 2.5 cm * Nodal Status: preoperatively N0 * Clear surgical margins: R0 * All grades G1 - G3 * Any hormonal receptor and HER-2 status * Informed consent Exclusion Criteria: * Gender: male * Tumor size: more than 2.5 cm * Nodal status greater than or equal to N1 pathologically * Multicentricity * Previous radiotherapy to the involved breast * Karnofsky Index \< 70% * Mixed connective tissue diseases e.g. rheumatoid poly arthritis, thromboangitis obliterans, systemic lupus * Distant metastases * Pregnancy in woman of child bearing age * Unable to provide written consent

Locations (1)

St. Joseph Hospital of Orange

Orange, California, United States

Outcomes

Primary Outcomes

Toxicity Assessment

Assessment of acute toxicity of breast irradiation according to CTC-toxicity Scoring - system: * End of initial surgical phase: Week 1, 4 * First Follow-up investigation: Month 2 Assessment of late toxicity according to NSABP scoring-systems at 6, 12, 24, 36, 48, and 60 months

Time frame: 5 years

Secondary Outcomes

Cosmetic Evaluation

Assessment of cosmetic outcome according to 5-point scoring system * Week 1, 2; Month 2, 6, 12, 24, 36, 48, 60 * At yearly follow-up (photodocumentation in standardized positions) for 5 years

Time frame: 5 years

Recurrence Assessment

Recurrence is assessed at month 6, 12, 24, 36, 48, 60

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.